$2.070
+0.150 (+7.25%)收盘时
IPA 资讯
IPA 事件
ImmunoPrecise Transforms into MindWalk, Signaling Transition to AI Platform
ImmunoPrecise Antibodies announced a unification under a single corporate brand, MindWalk, and a change of its Nasdaq ticker symbol to "HYFT". The company stated the new identity conveys its evolution into a Bio-Native AI platform business. "The company is expanding beyond specialized wet-lab services to commercialize an intelligence-platform model, launching SaaS offerings and supporting scalable partnerships," it stated.
ImmunoPrecise Antibodies reports LENSai Immunogenicity Screening study results
ImmunoPrecise Antibodies announced results of a newly expanded study demonstrating that its LENSai Immunogenicity Screening can reliably predict Anti-Drug-Antibody risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules."
ImmunoPrecise Antibodies regains compliance with Nasdaq
ImmunoPrecise Antibodies announced that it has received formal notification from Nasdaq confirming that the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. The notice, dated July 11, stated that for the 10 consecutive business days from June 26, through July 10, the closing bid price of the company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed.
ImmunoPrecise Antibodies announces new validation study on LENSai
ImmunoPrecise Antibodies announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT technology. "It's generally assumed that AI can only make accurate predictions if it has seen similar data before," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "But this benchmark proves otherwise: LENSai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate - it just needs the right kind."
ImmunoPrecise Antibodies provides update on dengue vaccine breakthrough
ImmunoPrecise provided an update following its June 5, press release. This new release details the downstream validation of the epitope identified in that initial announcement-demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. "This is a major step forward," said Jennifer Bath, CEO of ImmunoPrecise. "Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development." Following the recent discovery of a unique "Achilles' heel" shared by all four types of dengue virus, ImmunoPrecise has confirmed-using its patented Hyft technology and LENSai Immunogenicity Screener-that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。